1-12 of 12
Dorothy Romanus
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)

Larysa Sanchez, MD, Dasha Cherepanov, Dorothy Romanus, RPh, PhD, Aditya Raju, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-136597
Published: 2020
Journal Articles

Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)

Sikander Ailawadhi, MD, Dorothy Romanus, RPh, PhD, Dasha Cherepanov, PhD, Yu Yin, MS, MA, Meng-Ru Cheng, MSPH, Parameswaran Hari, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3164.
https://doi.org/10.1182/blood-2019-124301
Published: 2019
Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1827.
https://doi.org/10.1182/blood-2019-121658
Published: 2019
Journal Articles

Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study

Saad Z. Usmani, MD, Vania T. M. Hungria, MD PhD, Xavier Leleu, MD PhD, Hans C. Lee, MD, Faith E. Davies, MD, Caitlin L. Costello, MD, Robert M Rifkin, MD, Katja Weisel, MD, Ajai Chari, MD, Noemi Puig, MD PhD, Mario Boccadoro, MD, Gordon Cook, Jesus G. Berdeja, MD, Jeffrey A Zonder, MD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Jorge Vela-Ojeda, MD PhD, Roman Hajek, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jim Omel, MD, Brittany Demers, BS, BA, Dorothy Romanus, RPh, PhD, Kaili Ren, PhD, Tomas Skacel, MD PhD, Dawn Marie Stull, Pharm.D., BCOP, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3289.
https://doi.org/10.1182/blood-2018-99-112846
Published: 2018
Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1818.
https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818
Published: 2017
Journal Articles

Patterns and Determinants of Cancer-Directed Drug Therapy in Medicare Beneficiaries with Multiple Myeloma

Julia F Slejko, PhD, Dorothy Romanus, RPh, MSc, PhD, Daisuke Goto, PhD, Eberechukwu Onukwugha, PhD, Rahul Khairnar, MS, Brian Seal, RPh, MBA, PhD, Candice Yong, PhD, Jean Yared, MD
Journal: Blood
Blood (2016) 128 (22): 5926.
https://doi.org/10.1182/blood.V128.22.5926.5926
Published: 2016
Journal Articles

Determinants of Receipt of Stem Cell Transplant in Elderly Medicare Beneficiaries with Multiple Myeloma

Jean Yared, MD, Daisuke Goto, PhD, Eberechukwu Onukwugha, PhD, Rahul Khairnar, MS, Brian Seal, RPh, MBA, PhD, Dorothy Romanus, RPh, MSc, PhD, Candice Yong, PhD, Julia F Slejko, PhD
Journal: Blood
Blood (2016) 128 (22): 5927.
https://doi.org/10.1182/blood.V128.22.5927.5927
Published: 2016
Journal Articles

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Robert M Rifkin, Faith E Davies, MD, Antonio Palumbo, MD, Jeffrey Zonder, MD, Saulius K Girnius, MD, Caitlin L Costello, MD, Saad Z Usmani, MD FACP, Jesus G. Berdeja, MD, Jim Omel, Michael A Thompson, MD PhD, Jatin Shah, MD, J Sanford Schwartz, Roman Hajek, MD, Evangelos Terpos, MD PhD, Vânia Hungria, MD PhD, Maria-Victoria Mateos, MD PhD, Gordon Cook, Xavier Leleu, Andrew Spencer, Hartmut Goldschmidt, MD, Brian Seal, RPh, MBA, PhD, Chris L Pashos, PhD, Dawn Marie Stull, PharmD, FRACP, Dorothy Romanus, RPh, MSc, PhD, Roxanne Cacioppo, Jill A Bell, PhD, Shawn Yu, Katarina Luptakova, Liviu Niculescu, MD PhD, Stephen J Noga, Tomas Skacel, Ajai Chari, MD
Journal: Blood
Blood (2016) 128 (22): 5681.
https://doi.org/10.1182/blood.V128.22.5681.5681
Published: 2016
Journal Articles

Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD
Journal: Blood
Blood (2015) 126 (23): 4515.
https://doi.org/10.1182/blood.V126.23.4515.4515
Published: 2015
Journal Articles

Healthcare Resource Use and Costs Among Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Brian Seal, RPh, MBA, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD
Journal: Blood
Blood (2015) 126 (23): 4516.
https://doi.org/10.1182/blood.V126.23.4516.4516
Published: 2015
Journal Articles

Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Dorothy Romanus, RPh, MSc, PhD, Mehul Jhaveri, PharmD, PhD, Richard Labotka, MD MS, Henry Henk, PhD, Brian Seal, RPh, MBA, PhD
Journal: Blood
Blood (2015) 126 (23): 3309.
https://doi.org/10.1182/blood.V126.23.3309.3309
Published: 2015
Journal Articles

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Rita Percy, Michael E. Petrone, MD MPH, Scott Megaffin, Ayanna M Anene, BS, Jesse Ortendahl, MS, Dorothy Romanus, RPh, PhD, Tanya GK Bentley, PhD
Journal: Blood
Blood (2014) 124 (21): 1928.
https://doi.org/10.1182/blood.V124.21.1928.1928
Published: 2014